CONMED CORP (CNMD) Stock Fundamental Analysis
USA • New York Stock Exchange • NYSE:CNMD • US2074101013
42.48 USD
-0.32 (-0.75%)
Last: Feb 11, 2026, 02:07 PM
Taking everything into account, CNMD scores 5 out of 10 in our fundamental rating. CNMD was compared to 186 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of CNMD get a neutral evaluation. Nothing too spectacular is happening here. CNMD scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
- CNMD had positive earnings in the past year.
- In the past year CNMD had a positive cash flow from operations.
- Of the past 5 years CNMD 4 years were profitable.
- CNMD had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- CNMD has a better Return On Assets (2.77%) than 76.88% of its industry peers.
- The Return On Equity of CNMD (6.38%) is better than 80.11% of its industry peers.
- CNMD has a better Return On Invested Capital (4.94%) than 76.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.77% | ||
| ROE | 6.38% | ||
| ROIC | 4.94% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- CNMD's Profit Margin of 4.77% is fine compared to the rest of the industry. CNMD outperforms 77.42% of its industry peers.
- CNMD's Profit Margin has improved in the last couple of years.
- With a decent Operating Margin value of 9.99%, CNMD is doing good in the industry, outperforming 78.49% of the companies in the same industry.
- CNMD's Operating Margin has improved in the last couple of years.
- The Gross Margin of CNMD (54.22%) is comparable to the rest of the industry.
- In the last couple of years the Gross Margin of CNMD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.99% | ||
| PM (TTM) | 4.77% | ||
| GM | 54.22% |
OM growth 3Y15.88%
OM growth 5Y7.91%
PM growth 3YN/A
PM growth 5Y25.45%
GM growth 3Y1.06%
GM growth 5Y0.77%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CNMD is destroying value.
- CNMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- CNMD has an Altman-Z score of 1.90. This is not the best score and indicates that CNMD is in the grey zone with still only limited risk for bankruptcy at the moment.
- CNMD's Altman-Z score of 1.90 is fine compared to the rest of the industry. CNMD outperforms 60.75% of its industry peers.
- The Debt to FCF ratio of CNMD is 5.74, which is a neutral value as it means it would take CNMD, 5.74 years of fcf income to pay off all of its debts.
- CNMD has a Debt to FCF ratio of 5.74. This is in the better half of the industry: CNMD outperforms 77.96% of its industry peers.
- CNMD has a Debt/Equity ratio of 0.85. This is a neutral value indicating CNMD is somewhat dependend on debt financing.
- CNMD has a worse Debt to Equity ratio (0.85) than 72.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.85 | ||
| Debt/FCF | 5.74 | ||
| Altman-Z | 1.9 |
ROIC/WACC0.56
WACC8.83%
2.3 Liquidity
- CNMD has a Current Ratio of 2.10. This indicates that CNMD is financially healthy and has no problem in meeting its short term obligations.
- CNMD's Current ratio of 2.10 is in line compared to the rest of the industry. CNMD outperforms 40.86% of its industry peers.
- CNMD has a Quick Ratio of 2.10. This is a bad value and indicates that CNMD is not financially healthy enough and could expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 0.95, CNMD is doing worse than 77.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.1 | ||
| Quick Ratio | 0.95 |
3. Growth
3.1 Past
- CNMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.82%, which is quite good.
- The Earnings Per Share has been growing by 16.37% on average over the past years. This is quite good.
- CNMD shows a small growth in Revenue. In the last year, the Revenue has grown by 5.18%.
- CNMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.77% yearly.
EPS 1Y (TTM)10.82%
EPS 3Y20.27%
EPS 5Y16.37%
EPS Q2Q%6.72%
Revenue 1Y (TTM)5.18%
Revenue growth 3Y9.55%
Revenue growth 5Y9.77%
Sales Q2Q%7.88%
3.2 Future
- The Earnings Per Share is expected to grow by 7.09% on average over the next years.
- CNMD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.55% yearly.
EPS Next Y-1.76%
EPS Next 2Y4.92%
EPS Next 3Y7.09%
EPS Next 5YN/A
Revenue Next Year0.29%
Revenue Next 2Y2.72%
Revenue Next 3Y3.55%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- CNMD is valuated reasonably with a Price/Earnings ratio of 9.21.
- Based on the Price/Earnings ratio, CNMD is valued cheaply inside the industry as 95.16% of the companies are valued more expensively.
- CNMD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.03.
- The Price/Forward Earnings ratio is 9.38, which indicates a very decent valuation of CNMD.
- CNMD's Price/Forward Earnings ratio is rather cheap when compared to the industry. CNMD is cheaper than 96.24% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 27.97, CNMD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.21 | ||
| Fwd PE | 9.38 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, CNMD is valued cheaper than 90.32% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of CNMD indicates a rather cheap valuation: CNMD is cheaper than 98.92% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.85 | ||
| EV/EBITDA | 10.25 |
4.3 Compensation for Growth
- The decent profitability rating of CNMD may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.56
EPS Next 2Y4.92%
EPS Next 3Y7.09%
5. Dividend
5.1 Amount
- CNMD has a Yearly Dividend Yield of 1.97%. Purely for dividend investing, there may be better candidates out there.
- CNMD's Dividend Yield is rather good when compared to the industry average which is at 0.20. CNMD pays more dividend than 95.70% of the companies in the same industry.
- CNMD's Dividend Yield is comparable with the S&P500 average which is at 1.80.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.97% |
5.2 History
- The dividend of CNMD decreases each year by -0.01%.
- CNMD has paid a dividend for at least 10 years, which is a reliable track record.
- CNMD has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)-0.01%
Div Incr Years0
Div Non Decr Years12
5.3 Sustainability
- CNMD pays out 39.73% of its income as dividend. This is a sustainable payout ratio.
DP39.73%
EPS Next 2Y4.92%
EPS Next 3Y7.09%
NYSE:CNMD (2/11/2026, 2:07:29 PM)
42.48
-0.32 (-0.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-28 2026-01-28/amc
Earnings (Next)04-28 2026-04-28/amc
Inst Owners114.3%
Inst Owner Change-0.23%
Ins Owners0.29%
Ins Owner Change0.45%
Market Cap1.32B
Revenue(TTM)1.37B
Net Income(TTM)64.32M
Analysts73.33
Price Target49.57 (16.69%)
Short Float %7.55%
Short Ratio3.66
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.97% |
Yearly Dividend0.8
Dividend Growth(5Y)-0.01%
DP39.73%
Div Incr Years0
Div Non Decr Years12
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)0.52%
Min EPS beat(2)0.37%
Max EPS beat(2)0.66%
EPS beat(4)4
Avg EPS beat(4)6.26%
Min EPS beat(4)0.37%
Max EPS beat(4)14.78%
EPS beat(8)7
Avg EPS beat(8)4.08%
EPS beat(12)10
Avg EPS beat(12)-0.4%
EPS beat(16)13
Avg EPS beat(16)0.52%
Revenue beat(2)0
Avg Revenue beat(2)-0.89%
Min Revenue beat(2)-1.03%
Max Revenue beat(2)-0.75%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-1.03%
Max Revenue beat(4)0.51%
Revenue beat(8)1
Avg Revenue beat(8)-1.24%
Revenue beat(12)3
Avg Revenue beat(12)-1.58%
Revenue beat(16)4
Avg Revenue beat(16)-1.61%
PT rev (1m)0.41%
PT rev (3m)-21.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.42%
EPS NY rev (1m)-0.54%
EPS NY rev (3m)-6.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.62%
Revenue NY rev (1m)-0.36%
Revenue NY rev (3m)-4.83%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.21 | ||
| Fwd PE | 9.38 | ||
| P/S | 0.98 | ||
| P/FCF | 8.85 | ||
| P/OCF | 7.86 | ||
| P/B | 1.3 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.25 |
EPS(TTM)4.61
EY10.85%
EPS(NY)4.53
Fwd EY10.66%
FCF(TTM)4.8
FCFY11.3%
OCF(TTM)5.4
OCFY12.72%
SpS43.51
BVpS32.56
TBVpS-12.65
PEG (NY)N/A
PEG (5Y)0.56
Graham Number58.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.77% | ||
| ROE | 6.38% | ||
| ROCE | 6.7% | ||
| ROIC | 4.94% | ||
| ROICexc | 5.04% | ||
| ROICexgc | 17.43% | ||
| OM | 9.99% | ||
| PM (TTM) | 4.77% | ||
| GM | 54.22% | ||
| FCFM | 11.04% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y15.88%
OM growth 5Y7.91%
PM growth 3YN/A
PM growth 5Y25.45%
GM growth 3Y1.06%
GM growth 5Y0.77%
F-Score5
Asset Turnover0.58
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.85 | ||
| Debt/FCF | 5.74 | ||
| Debt/EBITDA | 4.09 | ||
| Cap/Depr | 25.13% | ||
| Cap/Sales | 1.38% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 80.15% | ||
| Profit Quality | 231.2% | ||
| Current Ratio | 2.1 | ||
| Quick Ratio | 0.95 | ||
| Altman-Z | 1.9 |
F-Score5
WACC8.83%
ROIC/WACC0.56
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.82%
EPS 3Y20.27%
EPS 5Y16.37%
EPS Q2Q%6.72%
EPS Next Y-1.76%
EPS Next 2Y4.92%
EPS Next 3Y7.09%
EPS Next 5YN/A
Revenue 1Y (TTM)5.18%
Revenue growth 3Y9.55%
Revenue growth 5Y9.77%
Sales Q2Q%7.88%
Revenue Next Year0.29%
Revenue Next 2Y2.72%
Revenue Next 3Y3.55%
Revenue Next 5YN/A
EBIT growth 1Y-35.26%
EBIT growth 3Y26.95%
EBIT growth 5Y18.45%
EBIT Next Year29.61%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.2%
OCF growth 3YN/A
OCF growth 5YN/A
CONMED CORP / CNMD FAQ
What is the ChartMill fundamental rating of CONMED CORP (CNMD) stock?
ChartMill assigns a fundamental rating of 5 / 10 to CNMD.
Can you provide the valuation status for CONMED CORP?
ChartMill assigns a valuation rating of 7 / 10 to CONMED CORP (CNMD). This can be considered as Undervalued.
How profitable is CONMED CORP (CNMD) stock?
CONMED CORP (CNMD) has a profitability rating of 6 / 10.
Can you provide the PE and PB ratios for CNMD stock?
The Price/Earnings (PE) ratio for CONMED CORP (CNMD) is 9.21 and the Price/Book (PB) ratio is 1.3.
What is the expected EPS growth for CONMED CORP (CNMD) stock?
The Earnings per Share (EPS) of CONMED CORP (CNMD) is expected to decline by -1.76% in the next year.